SCLERODERMA RESEARCH CONSULTANTS, LLC was founded in 2010 to advance clinical research, broaden educational efforts and elevate standards of care for persons with scleroderma.
Scleroderma (or systemic sclerosis) is an orphan disease affecting between 75 and 150,000 Americans and 2.5 million persons worldwide. Scleroderma means “hard skin” and refers to the tightening and thickening of the skin that is a clinical hallmark of the disorder. However, scleroderma is a far more complex disorder which includes extensive blood vessel damage, distinctive changes of the immune system and a high risk of involvement of the lungs, kidney, heart, intestines as well as other issues.
There is no current effective treatment although many patients benefit from treatments directed at specific organ complications. Increasing understanding of the disease process has many feeling optimistic that breakthrough treatments may soon be available.
The founder of Scleroderma Research Consultants is James R. Seibold, MD who is recognized as a world thought leader in scleroderma, its complications and related diseases including Raynaud phenomenon, interstitial lung disease and other scarring conditions.
Scleroderma Research Consultants provides care for persons with scleroderma while remaining focused on development of effective treatments. We invite you to explore our webpage.